Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease
Alzheimer’s disease (AD; progressive neurodegenerative disorder) is associated with cognitive and functional impairment with accompanying neuropsychiatric symptoms. The available pharmacological treatment is of a symptomatic nature and, as such, it does not modify the cause of AD. The currently used...
Main Authors: | Barbara Miziak, Barbara Błaszczyk, Stanisław J. Czuczwar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/5/458 |
Similar Items
-
Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease
by: Verónica Vidal, et al.
Published: (2021-04-01) -
A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs
by: Willy Smeralda, et al.
Published: (2023-11-01) -
Apitherapy in Post-Ischemic Brain Neurodegeneration of Alzheimer’s Disease Proteinopathy: Focus on Honey and Its Flavonoids and Phenolic Acids
by: Ryszard Pluta, et al.
Published: (2023-07-01) -
Comorbid epilepsy and depression—pharmacokinetic and pharmacodynamic drug interactions
by: Barbara Miziak, et al.
Published: (2022-10-01) -
Post-Ischemic Permeability of the Blood–Brain Barrier to Amyloid and Platelets as a Factor in the Maturation of Alzheimer’s Disease-Type Brain Neurodegeneration
by: Ryszard Pluta, et al.
Published: (2023-06-01)